Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B

March 2003
Clinical Infectious Diseases;3/15/2003, Vol. 36 Issue 6, p687
Academic Journal
YMDD variants of hepatitis B virus (HBV) emerge in some patients with chronic hepatitis B who receive lamivudine. YMDD variants were examined in 794 patients in 4 controlled studies of 1 year's duration. The long-term effects of YMDD variants were examined in a subset of patients treated up to 4 years. YMDD variants were detected by polymerase chain reaction (PCR) and restriction fragment-length polymorphism assays. After 1 year, YMDD variants were detected in 81 (24%) of 335 patients. In these patients, the median serum HBV DNA concentration at 1 year was <20% of the baseline level, and serum alanine transaminase (ALT) levels and liver histologic findings had significantly improved. In patients with YMDD variants who were treated for up to 4 years, median HBV DNA and ALT levels showed improvements. Sex, baseline body mass index, and HBV DNA level were associated with emergence of YMDD variants. Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy.


Related Articles

  • Clinical and Virological Improvement of Hepatitis B Virus -- Related or Hepatitis C Virus -- Related Chronic Hepatitis with Concomitant Hepatitis A Virus Infection. Sagnelli, Evangelista; Coppola, Nicola; Pisaturo, Mariantonietta; Pisapia, Raffaella; Onofrio, Mirella; Sagnelli, Caterina; Catuogno, Antonio; Scolastico, Carlo; Piccinino, Felice; Filippini, Pietro // Clinical Infectious Diseases;6/1/2006, Vol. 42 Issue 11, p1536 

    Background. We evaluated the clinical and virological characteristics of hepatitis A virus infection in persons concomitantly infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). Methods. We enrolled 21 patients with acute hepatitis A and chronic hepatitis with no sign of liver...

  • Molecular Therapeutics of HBV. Ruian Xu; Kexia Cai; Dexian Zheng; Hong Ma; Sue Xu; Sheung-tat Fan // Current Gene Therapy;Aug2003, Vol. 3 Issue 4, p341 

    The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body. Gene therapy is a...

  • Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. F. Moriconi; P. Colombatto; B. Coco; P. Ciccorossi; F. Oliveri; D. Flichman; A. M. Maina; R. Sacco; F. Bonino; M. R. Brunetto // Journal of Antimicrobial Chemotherapy (JAC);Aug2007, Vol. 60 Issue 2, p341 

    Objectives We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy. Methods The Pol/Rt A–F domains were...

  • Comparison of 12-Month Courses of Interferon-α -2b--Lamivudine Combination Therapy and Interferon-α -2b Monotherapy among Patients with Untreated Chronic Hepatitis B. Yalcin, Kendal; Degertekin, Halil; Yildiz, Fetin; Celik, Yusuf // Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1516 

    We compared the use of prolonged synchronous combination therapy with interferon (IFN)-α-2b and lami-vudine with the use of IFN-α-2b monotherapy in patients with untreated hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection. Thirty-three patients received...

  • Azathioprine/budesonide/methylprednisolone.  // Reactions Weekly;10/2/2010, Issue 1321, p9 

    The article describes cases in which two elderly men were given azathioprine and methylprednisolone or budesonide, and lated had a hepatitis B virus (HBV).

  • Imatinib.  // Reactions Weekly;5/8/2010, Issue 1300, p27 

    The article describes the case of a 48-year-old male patient who suffered from the reactivation of hepatitis B virus (HBV), leading to liver failure, while taking imatinib for chronic myeloid leukemia (CML).

  • Low replication and variability of HBV pre-core in concomitant infection with hepatitis B and hepatitis C viruses. De Mitri, M. S.; Morsica, G.; Cassini, R.; Bagaglio, S.; Andreone, P.; Bianchi, G.; Loggi, E.; Bernardi, M. // Archives of Virology;Feb2007, Vol. 152 Issue 2, p395 

    In an attempt to define the virological profile of HBV in HCV co-infection, we analysed the viral load, the infecting genotype, and the mutational pattern of the HBV pre-core region (pre-C), which is involved in viral encapsidation and DNA replication. Eighty-six patients were studied: 32 with...

  • A qualitative study of hepatitis B carriers' understanding of their chronic infection. Ngiap-Chuan Tan; Seng-Lian Cheah; Eng Kiong Teo; Kwok, Violet // Asia Pacific Family Medicine;Jul2005, Vol. 4, Special section p1 

    Aim: : This study aimed to determine hepatitis B (HBV) carriers' understanding of the etiology, pathology, monitoring and therapy of their chronic disease. Methods: A qualitative study using focus group discussion (FGD) and a semi-structured guideline to explore HBV carriers' understanding of...

  • Development of a Candidate Polyvalent Live Vaccine against Human Immunodeficiency, Hepatitis B, and Orthopox Viruses. Shchelkunov, S. N.; Nesterov, A. E.; Ryazankin, I. A.; Ignat'ev, G. M.; Sandakhchiev, L. S. // Doklady Biochemistry & Biophysics;May/Jun2003, Vol. 390 Issue 1-6, p180 

    Discusses the development of a candidate polyvalent live vaccine against human immunodeficiency virus (HIV), hepatitis B and orthopox viruses. History of HIV; Percentage of the world population infected with hepatitis B virus; Kinds of orthopox viruses.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics